1
|
Pan J, Tang J, Gai J, Jin Y, Tang B, Fan X. Exploring the mechanism of Ginkgo biloba L. leaves in the treatment of vascular dementia based on network pharmacology, molecular docking, and molecular dynamics simulation. Medicine (Baltimore) 2023; 102:e33877. [PMID: 37233418 PMCID: PMC10219709 DOI: 10.1097/md.0000000000033877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 05/08/2023] [Indexed: 05/27/2023] Open
Abstract
BACKGROUND Ginkgo biloba L. leaves (GBLs) play a substantial role in the treatment of vascular dementia (VD); however, the underlying mechanisms of action are unclear. OBJECTIVE This study was conducted to investigate the mechanisms of action of GBLs in the treatment of VD through network pharmacology, molecular docking, and molecular dynamics simulations. METHODS The active ingredients and related targets of GBLs were screened using the traditional Chinese medicine systems pharmacology, Swiss Target Prediction and GeneCards databases, and the VD-related targets were screened using the OMIM, DrugBank, GeneCards, and DisGeNET databases, and the potential targets were identified using a Venn diagram. We used Cytoscape 3.8.0 software and the STRING platform to construct traditional Chinese medicine-active ingredient-potential target and protein-protein interaction networks, respectively. After gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis of potential targets using the DAVID platform, the binding affinity between key active ingredients and targets was analyzed by molecular docking, and finally, the top 3 proteins-ligand pairs with the best binding were simulated by molecular dynamics to verify the molecular docking results. RESULTS A total of 27 active ingredients of GBLs were screened and 274 potential targets involved in the treatment of VD were identified. Quercetin, luteolin, kaempferol, and ginkgolide B were the core ingredients for treatment, and AKT1, TNF, IL6, VEGFA, IL1B, TP53, CASP3, SRC, EGFR, JUN, and EGFR were the main targets of action. The main biological processes involved apoptosis, inflammatory response, cell migration, lipopolysaccharide response, hypoxia response, and aging. PI3K/Akt appeared to be a key signaling pathway for GBLs in the treatment of VD. Molecular docking displayed strong binding affinity between the active ingredients and the targets. Molecular dynamics simulation results further verified the stability of their interactions. CONCLUSION SUBSECTIONS This study revealed the potential molecular mechanisms involved in the treatment of VD by GBLs using multi-ingredient, multi-target, and multi-pathway interactions, providing a theoretical basis for the clinical treatment and lead drug development of VD.
Collapse
Affiliation(s)
- Jienuo Pan
- School of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Jiqin Tang
- School of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Jialin Gai
- School of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Yilan Jin
- School of International Education, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Bingshun Tang
- School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Xiaohua Fan
- Department of Rehabilitation Medicine, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| |
Collapse
|
2
|
Tan Z, Yang G, Qiu J, Yan W, Liu Y, Ma Z, Li J, Liu J, Shan N. Quercetin Alleviates Demyelination Through Regulating Microglial Phenotype Transformation to Mitigate Neuropsychiatric Symptoms in Mice with Vascular Dementia. Mol Neurobiol 2022; 59:3140-3158. [PMID: 35267135 DOI: 10.1007/s12035-021-02712-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 12/21/2021] [Indexed: 12/12/2022]
Abstract
Cerebral hypoperfusion plays a pivotal role in the ictus and development of vascular dementia (VaD) with neuropsychiatric symptoms. To date, few pharmacological interventions for neuropsychiatric symptoms are available in the VaD patients with neuropsychiatric impairments. Here, our results demonstrated that the extent of demyelination was dramatically deteriorated and the thickness of myelin sheath was evidently decreased in the presence of cerebral hypoperfusion, whereas Quercetin possessed the potential of abrogating these effects at least in part, then relieving anxiety and depression-like behavior when mice exposed to bilateral carotid artery stenosis (BCAS)/chronic restraint stress (CRS). The underlying mechanism was that Quercetin facilitated secretion of anti-inflammatory cytokines (IL-4 and IL-10) and in turn decreased production of pro-inflammatory factors (TNF-α and IL-1β) due to regulating microglial phenotype transformation, thereafter enhancing the microglial engulfment ability of myelin fragments in vitro and in vivo. Collectively, the results demonstrated that that Quercetin mediated microglial transformation into anti-inflammatory phenotype to reduce demyelination in ventral hippocampus (vHIP), thereafter mitigating neuropsychiatric deficits (including anxiety and depression). The present research broadens the therapeutic scope of Quercetin in central nervous system (CNS) disorders with presence of white matter damage and/or the insufficient activation of anti-inflammatory microglia, particularly for vascular dementia with/without neuropsychiatric symptoms.
Collapse
Affiliation(s)
- Zihu Tan
- Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, 430061, China.,Hubei Provincial Academy of Traditional Chinese Medicine, 430061, Wuhan, Hubei, People's Republic of China
| | - Guang Yang
- Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, 430061, China.,Hubei Provincial Academy of Traditional Chinese Medicine, 430061, Wuhan, Hubei, People's Republic of China
| | - Jing Qiu
- Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, 430061, China.,Hubei Provincial Academy of Traditional Chinese Medicine, 430061, Wuhan, Hubei, People's Republic of China
| | - Wenjing Yan
- Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, 430061, China
| | - Yu Liu
- Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, 430061, China.,Hubei Provincial Academy of Traditional Chinese Medicine, 430061, Wuhan, Hubei, People's Republic of China
| | - Zhengling Ma
- Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, 430061, China
| | - Jia Li
- College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine/Hubei Provincial Collaborative Innovation Center of Preventive Treatment By Acupuncture and Moxibustion, Wuhan, 430061, China
| | - Jing Liu
- College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine/Hubei Provincial Collaborative Innovation Center of Preventive Treatment By Acupuncture and Moxibustion, Wuhan, 430061, China
| | - Nan Shan
- Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China. .,Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, 430061, China. .,Hubei Provincial Academy of Traditional Chinese Medicine, 430061, Wuhan, Hubei, People's Republic of China.
| |
Collapse
|
3
|
Perea Vega ML, Sanchez MS, Fernández G, Paglini MG, Martin M, de Barioglio SR. Ghrelin treatment leads to dendritic spine remodeling in hippocampal neurons and increases the expression of specific BDNF-mRNA species. Neurobiol Learn Mem 2021; 179:107409. [PMID: 33609738 DOI: 10.1016/j.nlm.2021.107409] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 02/02/2021] [Accepted: 02/11/2021] [Indexed: 11/15/2022]
Abstract
Ghrelin (Gr) is an orexigenic peptide that acts via its specific receptor, GHSR-1a distributed throughout the brain, being mainly enriched in pituitary, cortex and hippocampus (Hp) modulating a variety of brain functions. Behavioral, electrophysiological and biochemical evidence indicated that Gr modulates the excitability and the synaptic plasticity in Hp. The present experiments were designed in order to extend the knowledge about the Gr effect upon structural synaptic plasticity since morphological and quantitative changes in spine density after Gr administration were analyzed "in vitro" and "in vivo". The results show that Gr administered to hippocampal cultures or stereotactically injected in vivo to Thy-1 mice increases the density of dendritic spines (DS) being the mushroom type highly increased in secondary and tertiary extensions. Spines classified as thin type were increased particularly in primary extensions. Furthermore, we show that Gr enhances selectively the expression of BDNF-mRNA species.
Collapse
Affiliation(s)
- M L Perea Vega
- Departamento de Farmacología, Instituto de Farmacología Experimental-IFEC-CONICET-Universidad Nacional de Córdoba, Argentina
| | - M S Sanchez
- Laboratorio de Neurobiología, Instituto de Investigación Médica Mercedes y Martín Ferreyra-INIMEC-CONICET-Universidad Nacional de Córdoba. Córdoba, Argentina; Instituto Universitario Ciencias Biomédicas Córdoba, Córdoba, Argentina
| | - G Fernández
- Laboratorio de Neurofisiología, Instituto de Investigación Médica Mercedes y Martín Ferreyra, INIMEC-CONICET, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - M G Paglini
- Laboratorio de Neurofisiología, Instituto de Investigación Médica Mercedes y Martín Ferreyra, INIMEC-CONICET, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - M Martin
- Laboratorio de Neurobiología, Instituto de Investigación Médica Mercedes y Martín Ferreyra-INIMEC-CONICET-Universidad Nacional de Córdoba. Córdoba, Argentina
| | - S R de Barioglio
- Departamento de Farmacología, Instituto de Farmacología Experimental-IFEC-CONICET-Universidad Nacional de Córdoba, Argentina.
| |
Collapse
|